Cite
HARVARD Citation
Glueck, C. et al. (2016). Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dl despite maximal tolerated cholesterol lowering therapy. Lipids in health and disease. 15 (1), pp. 1-6. [Online].